NU
Nuvalent
NUVL·NASDAQCambridge MAFounded 2018200 employees
Mid CapbiotechPublicOncology
Platform: Brain-pen Kinase
Market Cap
$9B
All Drugs
4
Clinical Trials
10
Failed / Terminated
4
FDA Approved
2
Stock Price & Catalysts (NUVL)
Loading NUVL stock data...
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Doxalemzoparlimab | NUV-8904 | Approved | 1 | AHR | WMADHD | ||
| Polatuximab | NUV-3464 | Approved | 4 | PD-L1 | Ovarian CaPNH | ||
| NUV-2032 | NUV-2032 | Preclinical | 1 | KIF18A | ET | ||
| NUV-283 | NUV-283 | Phase 3 | 4 | B7-H3 | Parkinson's |
SEC Filings & Financial Documents
Insider Trading Activity
Fetching insider trading data from SEC EDGAR...
Catalyst Events (9)